MedTrace Logo

SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI)

NCT01046838 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-05-24

No results posted yet for this study

Summary

In patients with Doppler echocardiographic signs of elevated LV filling pressures despite preserved LV systolic function after AMI treatment with the phosphodiesterase inhibitor sildenafil 40 mg three times daily for 9 weeks will compared with placebo

1. Improve resting LV filling and cardiac hemodynamics.
2. Improve exercise capacity.
3. Improve filling pattern and cardiac hemodynamics during exercise.

Conditions

  • Heart Failure, Diastolic

Interventions

DRUG

Sildenafil

40 mg three times daily for 9 weeks

DRUG

Placebo

tablet 3 times daily for 9 weeks

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Jacob E Mueller

    lead OTHER

Principal Investigators

  • Jacob E Møller, MD, Phd, DmSci · Rigshospitalet, Denmark

  • Mads J Andersen, MD · The Heart Center, Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-03-31
Completion
2012-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046838 on ClinicalTrials.gov